Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus.

Autor: Gilmore SA; Gilead Sciences, Inc., Foster City, California, United States America., Tam D; Gilead Sciences, Inc., Foster City, California, United States America., Cheung TL; Gilead Sciences, Inc., Foster City, California, United States America., Snyder C; Gilead Sciences, Inc., Foster City, California, United States America., Farand J; Gilead Sciences, Inc., Foster City, California, United States America., Dick R; Gilead Sciences, Inc., Foster City, California, United States America., Matles M; Gilead Sciences, Inc., Foster City, California, United States America., Feng JY; Gilead Sciences, Inc., Foster City, California, United States America., Ramirez R; Gilead Sciences, Inc., Foster City, California, United States America., Li L; Gilead Sciences, Inc., Foster City, California, United States America., Yu H; Gilead Sciences, Inc., Foster City, California, United States America., Xu Y; Gilead Sciences, Inc., Foster City, California, United States America., Barnes D; Gilead Sciences, Inc., Foster City, California, United States America., Czerwieniec G; Gilead Sciences, Inc., Foster City, California, United States America., Brendza KM; Gilead Sciences, Inc., Foster City, California, United States America., Appleby TC; Gilead Sciences, Inc., Foster City, California, United States America., Birkus G; Gilead Sciences, Inc., Foster City, California, United States America., Willkom M; Gilead Sciences, Inc., Foster City, California, United States America., Kobayashi T; Gilead Sciences, Inc., Foster City, California, United States America., Paoli E; Gilead Sciences, Inc., Foster City, California, United States America., Labelle M; EpiTherapeutics ApS, Copenhagen, Denmark., Boesen T; EpiTherapeutics ApS, Copenhagen, Denmark.; Novo Nordisk A/S, Bagsvaerd, Denmark., Tay CH; Gilead Sciences, Inc., Foster City, California, United States America., Delaney WE 4th; Gilead Sciences, Inc., Foster City, California, United States America., Notte GT; Gilead Sciences, Inc., Foster City, California, United States America., Schmitz U; Gilead Sciences, Inc., Foster City, California, United States America., Feierbach B; Gilead Sciences, Inc., Foster City, California, United States America.

Publikováno v: PloS one [PLoS One] 2022 Dec 07; Vol. 17 (12), pp. e0271145. Date of Electronic Publication: 2022 Dec 07 (Print Publication: 2022).

Archived HIV-1 Drug Resistance Mutations: Role of Proviral HIV-1 DNA Genotype for the Management of Virological Responder People Living with HIV.

Autor: Campagna, Roberta¹ (AUTHOR) chiara.nonne@uniroma1.it, Nonne, Chiara¹ (AUTHOR), Antonelli, Guido¹ (AUTHOR), Turriziani, Ombretta¹ (AUTHOR)

Publikováno v: Viruses (1999-4915). Nov2024, Vol. 16 Issue 11, p1697. 18p.

Comments on "High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence".

Autor: Alidjinou EK; Laboratoire de Virologie, Univ Lille, CHU de Lille, Lille, France.

Publikováno v: Journal of medical virology [J Med Virol] 2024 Oct; Vol. 96 (10), pp. e29950.

Treatment Management Challenges in Naïve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation.

Autor: Mimtsoudis, Iordanis¹ (AUTHOR) jordymim@hotmail.com, Tsachouridou, Olga¹ (AUTHOR) metallidissimeon@yahoo.gr, Akinosoglou, Karolina² (AUTHOR) akin@upatras.gr, Metallidis, Symeon¹ (AUTHOR)

Publikováno v: Viruses (1999-4915). Sep2024, Vol. 16 Issue 9, p1392. 24p.

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.

Autor: Andreatta K; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA., Willkom M; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA., Martin R; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA., Chang S; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA., Wei L; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA., Liu H; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA., Liu YP; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA., Graham H; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA., Quirk E; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA., Martin H; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA., White KL; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.

Publikováno v: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Dec 01; Vol. 74 (12), pp. 3555-3564.